Switch to:
Also traded in: Austria, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISRG's Cash-to-Debt is ranked higher than
98% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. ISRG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISRG' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.35  Med: No Debt Max: No Debt
Current: No Debt
6.35
No Debt
Equity-to-Asset 0.82
ISRG's Equity-to-Asset is ranked higher than
80% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ISRG: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
ISRG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.65  Med: 0.86 Max: 0.89
Current: 0.82
0.65
0.89
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
97% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 68.39 vs. ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 29.52
Beneish M-Score: -2.81
WACC vs ROIC
8.80%
22.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 33.71
ISRG's Operating Margin % is ranked higher than
96% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ISRG: 33.71 )
Ranked among companies with meaningful Operating Margin % only.
ISRG' s Operating Margin % Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 33.71
25.56
40.3
Net Margin % 21.09
ISRG's Net Margin % is ranked higher than
91% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 1.42 vs. ISRG: 21.09 )
Ranked among companies with meaningful Net Margin % only.
ISRG' s Net Margin % Range Over the Past 10 Years
Min: 19.65  Med: 25.86 Max: 30.14
Current: 21.09
19.65
30.14
ROE % 13.69
ISRG's ROE % is ranked higher than
83% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ISRG: 13.69 )
Ranked among companies with meaningful ROE % only.
ISRG' s ROE % Range Over the Past 10 Years
Min: 12.17  Med: 17.77 Max: 21.36
Current: 13.69
12.17
21.36
ROA % 11.81
ISRG's ROA % is ranked higher than
89% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: -0.20 vs. ISRG: 11.81 )
Ranked among companies with meaningful ROA % only.
ISRG' s ROA % Range Over the Past 10 Years
Min: 10.59  Med: 15.21 Max: 18.44
Current: 11.81
10.59
18.44
ROC (Joel Greenblatt) % 151.99
ISRG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. ISRG: 151.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISRG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 117.99  Med: 186.03 Max: 245.9
Current: 151.99
117.99
245.9
3-Year Revenue Growth Rate 12.60
ISRG's 3-Year Revenue Growth Rate is ranked higher than
73% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. ISRG: 12.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISRG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.2 Max: 57.1
Current: 12.6
0
57.1
3-Year EBITDA Growth Rate 21.90
ISRG's 3-Year EBITDA Growth Rate is ranked higher than
70% of the 235 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ISRG: 21.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISRG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: 25.65 Max: 318.7
Current: 21.9
-62.8
318.7
3-Year EPS without NRI Growth Rate 15.30
ISRG's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ISRG: 15.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISRG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -61.5  Med: 18.1 Max: 76.8
Current: 15.3
-61.5
76.8
GuruFocus has detected 5 Warning Signs with Intuitive Surgical Inc ISRG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISRG's 30-Y Financials

Financials (Next Earnings Date: 2018-04-18)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ISRG Guru Trades in Q1 2017

George Soros 400 sh (New)
Paul Tudor Jones 15,664 sh (+1196.69%)
Steven Cohen 34,600 sh (+183.61%)
Vanguard Health Care Fund 186,869 sh (unchged)
Joel Greenblatt Sold Out
John Hussman Sold Out
Pioneer Investments Sold Out
Lee Ainslie Sold Out
Ray Dalio Sold Out
Jim Simons 194,970 sh (-2.46%)
Ron Baron 10,923 sh (-2.61%)
John Paulson 7,400 sh (-26.73%)
Robert Olstein 8,600 sh (-30.08%)
Jeremy Grantham 31,736 sh (-40.38%)
Manning & Napier Advisors, Inc 51,049 sh (-68.03%)
Eaton Vance Worldwide Health Sciences Fund 46,205 sh (-17.75%)
» More
Q2 2017

ISRG Guru Trades in Q2 2017

Lee Ainslie 4,240 sh (New)
Jim Simons 307,100 sh (+57.51%)
John Paulson 10,200 sh (+37.84%)
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
George Soros Sold Out
Ron Baron 10,344 sh (-5.30%)
Vanguard Health Care Fund 161,369 sh (-13.65%)
Manning & Napier Advisors, Inc 40,653 sh (-20.36%)
Robert Olstein 4,200 sh (-51.16%)
Eaton Vance Worldwide Health Sciences Fund 39,163 sh (-15.24%)
» More
Q3 2017

ISRG Guru Trades in Q3 2017

Paul Tudor Jones 2,025 sh (New)
Steven Cohen 23,200 sh (New)
Jim Simons 428,600 sh (+39.56%)
Lee Ainslie 5,501 sh (+29.74%)
John Paulson Sold Out
Ron Baron 9,682 sh (-6.40%)
Manning & Napier Advisors, Inc 36,845 sh (-9.37%)
Robert Olstein 3,400 sh (-19.05%)
Vanguard Health Care Fund 92,705 sh (-42.55%)
Eaton Vance Worldwide Health Sciences Fund 30,965 sh (-20.93%)
» More
Q4 2017

ISRG Guru Trades in Q4 2017

Joel Greenblatt 12,960 sh (New)
John Hussman 10,000 sh (New)
Pioneer Investments 51,611 sh (New)
Caxton Associates 3,612 sh (New)
Lee Ainslie 27,020 sh (+63.73%)
Jim Simons 1,440,600 sh (+12.04%)
Steven Cohen Sold Out
Paul Tudor Jones 6,064 sh (-0.18%)
Ron Baron 27,720 sh (-4.57%)
Robert Olstein 8,000 sh (-21.57%)
Vanguard Health Care Fund 166,328 sh (-40.19%)
Eaton Vance Worldwide Health Sciences Fund 74,076 sh (-20.26%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-12-31 Reduce -40.19%0.08%$353.49 - $403.7 $ 427.5114%166,328
Ron Baron 2017-12-31 Reduce -4.57%$353.49 - $403.7 $ 427.5114%27,720
Joel Greenblatt 2017-12-31 New Buy0.07%$353.49 - $403.7 $ 427.5114%12,960
Robert Olstein 2017-12-31 Reduce -21.57%0.1%$353.49 - $403.7 $ 427.5114%8,000
Vanguard Health Care Fund 2017-09-30 Reduce -42.55%0.14%$307.22 - $348.79 $ 427.5131%278,115
Ron Baron 2017-09-30 Reduce -6.40%$307.22 - $348.79 $ 427.5131%29,046
Robert Olstein 2017-09-30 Reduce -19.05%0.1%$307.22 - $348.79 $ 427.5131%10,200
John Paulson 2017-09-30 Sold Out 0.13%$307.22 - $348.79 $ 427.5131%0
Vanguard Health Care Fund 2017-06-30 Reduce -13.65%0.04%$253.11 - $318.05 $ 427.5149%484,107
Ron Baron 2017-06-30 Reduce -5.30%$253.11 - $318.05 $ 427.5149%31,032
John Paulson 2017-06-30 Add 37.84%0.04%$253.11 - $318.05 $ 427.5149%30,600
Robert Olstein 2017-06-30 Reduce -51.16%0.43%$253.11 - $318.05 $ 427.5149%12,600
George Soros 2017-06-30 Sold Out 0.01%$253.11 - $318.05 $ 427.5149%0
Ron Baron 2017-03-31 Reduce -2.61%$209.83 - $255.77 $ 427.5181%32,769
Robert Olstein 2017-03-31 Reduce -30.08%0.3%$209.83 - $255.77 $ 427.5181%25,800
John Paulson 2017-03-31 Reduce -26.73%0.02%$209.83 - $255.77 $ 427.5181%22,200
George Soros 2017-03-31 New Buy0.01%$209.83 - $255.77 $ 427.5181%1,200
Joel Greenblatt 2017-03-31 Sold Out 0.02%$209.83 - $255.77 $ 427.5181%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:BSX, NYSE:SYK, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NYSE:TFX, NYSE:VAR, NAS:ABMD, XSWX:SOON, OCSE:WDH, ASX:COH, SZSE:300003, XPAR:DIM, LSE:CTEC, NZSE:FPH, NAS:MASI, NYSE:GMED, OCSE:AMBU B, OCSE:GN » details
Traded in other countries:ISRG.Austria, IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Headquarter Location:USA
Intuitive Surgical Inc designs, manufactures, markets da Vinci Surgical Systems, and related instruments. The da Vinci surgery, combines the benefits of minimally invasive surgery for patients with the ease of use, precision and dexterity of open surgery.

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. Intuitive Surgical also provides the instrumentation, disposable accessories, and warranty services for the system. The firm has placed roughly 4,000 da Vinci systems in hospitals worldwide, with 2,600 installations in the U.S. and a growing number in emerging markets.

Guru Investment Theses on Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical - Feb 21, 2017

Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s robotic systems, implying substantial runway for growth.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical - Feb 13, 2017

After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed using its robotic system, which together with annual service fees provides recurring revenue. Management has defined its current addressable market as four million procedures, but we believe Intuitive will continue to expand its addressable market by entering new procedure areas. The company has an exciting pipeline of new products, including a single port system that will enable new procedures and a robotic catheter system that will enable lung tissue biopsies to be taken minimally invasively. In the fourth quarter, the stock pulled back despite a strong fundamental outlook because investors became concerned that the repeal of the Affordable Care Act would cause Intuitive’s hospital customers to cut capital spending, which would negatively impact Intuitive’s system sales. We saw this pull-back as short-sighted and bought the stock. We think Intuitive can grow revenue and earnings at attractive rates over the long term.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

3 Stocks Move on Wednesday Intuitive Surgical, Tandem Diabetes rise, AstraZeneca falls
Intuitive Surgical Inc. (NASDAQ:ISRG) gained more than 6% on Wednesday after releasing preliminary fourth-quarter 2017 earnings results at the JPMorgan Healthcare Conference. Read more...
Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2017 Results
Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2017 Results
Vanguard Health Care Fund Trims Positions in Vertex, Regeneron, Illumina Fund's largest 3rd-quarter sales
Founded in 1984, the Vanguard Health Care Fund (Trades, Portfolio) is managed by Jean Hynes. During the third quarter, the fund reduced its positions in the following stocks: Read more...
New Study Reports Favorable Results for Intuitive Surgical’s Flexible Robotics Platform
Largest Insider Trades of the Week Radius Health, Del Taco Restaurants among stocks bought by insiders
The GuruFocus All-In-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “October 2017” and All Insider Sales to “$5,000,000+." Read more...
Intuitive Surgical Reports New Employee Option Grants for August 2017
Intuitive Surgical Board of Directors Approves a Three-for-One Stock Split
Intuitive Surgical Reports New Employee Option Grants for July 2017
Intuitive Surgical Reports New Employee Option Grants for June 2017

Ratios

vs
industry
vs
history
PE Ratio 75.40
ISRG's PE Ratio is ranked lower than
86% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.67 vs. ISRG: 75.40 )
Ranked among companies with meaningful PE Ratio only.
ISRG' s PE Ratio Range Over the Past 10 Years
Min: 17.76  Med: 37.71 Max: 107.13
Current: 75.4
17.76
107.13
Forward PE Ratio 42.37
ISRG's Forward PE Ratio is ranked lower than
85% of the 48 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ISRG: 42.37 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 75.40
ISRG's PE Ratio without NRI is ranked lower than
85% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 28.67 vs. ISRG: 75.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
ISRG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.73  Med: 37.7 Max: 106.5
Current: 75.4
17.73
106.5
Price-to-Owner-Earnings 60.53
ISRG's Price-to-Owner-Earnings is ranked lower than
72% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 35.70 vs. ISRG: 60.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ISRG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.18  Med: 40.68 Max: 110.25
Current: 60.53
18.18
110.25
PB Ratio 10.14
ISRG's PB Ratio is ranked lower than
89% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.85 vs. ISRG: 10.14 )
Ranked among companies with meaningful PB Ratio only.
ISRG' s PB Ratio Range Over the Past 10 Years
Min: 2.81  Med: 6.02 Max: 15.72
Current: 10.14
2.81
15.72
PS Ratio 15.89
ISRG's PS Ratio is ranked lower than
85% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. ISRG: 15.89 )
Ranked among companies with meaningful PS Ratio only.
ISRG' s PS Ratio Range Over the Past 10 Years
Min: 4.15  Med: 9.79 Max: 24.3
Current: 15.89
4.15
24.3
Price-to-Free-Cash-Flow 52.24
ISRG's Price-to-Free-Cash-Flow is ranked lower than
68% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 31.00 vs. ISRG: 52.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ISRG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.4  Med: 31.21 Max: 94.73
Current: 52.24
18.4
94.73
Price-to-Operating-Cash-Flow 43.51
ISRG's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 20.56 vs. ISRG: 43.51 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ISRG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.33  Med: 26.85 Max: 84.58
Current: 43.51
11.33
84.58
EV-to-EBIT 43.67
ISRG's EV-to-EBIT is ranked lower than
78% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.04 vs. ISRG: 43.67 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.5 Max: 74.4
Current: 43.67
10.2
74.4
EV-to-EBITDA 39.91
ISRG's EV-to-EBITDA is ranked lower than
83% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.40 vs. ISRG: 39.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 24.1 Max: 61.9
Current: 39.91
9.4
61.9
EV-to-Revenue 14.72
ISRG's EV-to-Revenue is ranked lower than
81% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 3.64 vs. ISRG: 14.72 )
Ranked among companies with meaningful EV-to-Revenue only.
ISRG' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.6  Med: 9.1 Max: 24
Current: 14.72
3.6
24
PEG Ratio 12.57
ISRG's PEG Ratio is ranked lower than
89% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ISRG: 12.57 )
Ranked among companies with meaningful PEG Ratio only.
ISRG' s PEG Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.05 Max: 18.01
Current: 12.57
0.13
18.01
Shiller PE Ratio 94.66
ISRG's Shiller PE Ratio is ranked lower than
76% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 47.20 vs. ISRG: 94.66 )
Ranked among companies with meaningful Shiller PE Ratio only.
ISRG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.08  Med: 72.88 Max: 282.22
Current: 94.66
44.08
282.22
Current Ratio 3.99
ISRG's Current Ratio is ranked higher than
70% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ISRG: 3.99 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 3.02  Med: 4.52 Max: 5.45
Current: 3.99
3.02
5.45
Quick Ratio 3.65
ISRG's Quick Ratio is ranked higher than
74% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ISRG: 3.65 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 2.68  Med: 4.22 Max: 5.14
Current: 3.65
2.68
5.14
Days Inventory 84.06
ISRG's Days Inventory is ranked higher than
73% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 141.33 vs. ISRG: 84.06 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 68.81  Med: 76.79 Max: 91.85
Current: 84.06
68.81
91.85
Days Sales Outstanding 59.72
ISRG's Days Sales Outstanding is ranked higher than
61% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 66.85 vs. ISRG: 59.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 61.12 Max: 71.25
Current: 59.72
48.57
71.25
Days Payable 32.21
ISRG's Days Payable is ranked lower than
78% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 61.22 vs. ISRG: 32.21 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 31.77 Max: 34.57
Current: 32.21
23.81
34.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 247 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. ISRG: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -1.5 Max: 2.4
Current: -0.7
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 51.63
ISRG's Price-to-Net-Cash is ranked lower than
86% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 13.00 vs. ISRG: 51.63 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISRG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.46  Med: 20.74 Max: 60.14
Current: 51.63
4.46
60.14
Price-to-Net-Current-Asset-Value 26.94
ISRG's Price-to-Net-Current-Asset-Value is ranked lower than
85% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: 7.36 vs. ISRG: 26.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISRG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.71  Med: 11.51 Max: 28.33
Current: 26.94
3.71
28.33
Price-to-Tangible-Book 10.65
ISRG's Price-to-Tangible-Book is ranked lower than
78% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ISRG: 10.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISRG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.5  Med: 5.66 Max: 16.47
Current: 10.65
3.5
16.47
Price-to-Intrinsic-Value-Projected-FCF 3.73
ISRG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
70% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 2.37 vs. ISRG: 3.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ISRG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.32 Max: 14.7
Current: 3.73
1.45
14.7
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.45
ISRG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
76% of the 29 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ISRG: 3.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ISRG' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.19  Med: 1.75 Max: 4.42
Current: 3.45
1.19
4.42
Price-to-Median-PS-Value 1.63
ISRG's Price-to-Median-PS-Value is ranked lower than
76% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ISRG: 1.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISRG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.95 Max: 2.15
Current: 1.63
0.32
2.15
Price-to-Peter-Lynch-Fair-Value 12.12
ISRG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
100% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ISRG: 12.12 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ISRG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.92  Med: 1.37 Max: 10.35
Current: 12.12
0.92
10.35
Price-to-Graham-Number 5.97
ISRG's Price-to-Graham-Number is ranked lower than
85% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. ISRG: 5.97 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ISRG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.13  Med: 3.58 Max: 7.99
Current: 5.97
2.13
7.99
Earnings Yield (Greenblatt) % 2.29
ISRG's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ISRG: 2.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISRG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 3.8 Max: 9.8
Current: 2.29
1.3
9.8
Forward Rate of Return (Yacktman) % 7.82
ISRG's Forward Rate of Return (Yacktman) % is ranked higher than
53% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. ISRG: 7.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ISRG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.1  Med: 28.35 Max: 145.5
Current: 7.82
1.1
145.5

More Statistics

Revenue (TTM) (Mil) $3,128.90
EPS (TTM) $ 5.67
Beta0.98
Short Percentage of Float2.09%
52-Week Range $242.26 - 452.00
Shares Outstanding (Mil)112.30

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 3,564 4,212
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 10.02 11.88
EPS without NRI ($) 10.02 11.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.63%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}